跳至主要内容
临床试验/RPCEC00000148
RPCEC00000148招募中1 期

Pharmacokinetics of the Intralesional administration with two doses of rhEGF (75 µg and 225 µg) in patients with advance Diabetic Foot Ulcers

Center for Genetic Engineering and Biotechnology (CIGB)0 个研究点目标入组 25 人开始时间: 2013年2月8日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Treatment

入排标准

年龄范围
18 years 至 /A (No limit)(—)
性别
All

入选标准

  • 1. Written, informed consent to participate, previous to any procedure described in the protocol. 2. Age = 18 years. 3. Size of the ulcer = 10 cm2 and = 30 cm2. 4. Deep and ischemic ulcers, to reach subcutaneous cellular tissue up to tendon or joint capsule, bone, with or not bone exposition, without osteomyelitis and infection. 5. Pressure index Ankle/Brachial = 0,6 < 0,9. 6. Ulcers = 4 weeks of evolution (treated or not). 7. Women into fertile age should use an effective contraceptive method until three months after the treatment has concluded.

排除标准

  • 1. Hemoglobin <100 g/L. 2. Connective tissue diseases. 3. Morbid obesity (body mass index > 40). 4. Use of drugs that could interfere (corticosteroids or immunosuppressants) or favor the healing (prostaglandin and others growth factors). 5. Systemic decompensated or severe diseases (Ischemic heart disease or diabetic coma), moderaty or severe liver failure (ALT, AST or GGT twices over the normal value and prothrombin values 3 sec. over the control), or renal failure with creatinine values > 200 µmol/L. 6. Signs of clinical malnutrition or albumin levels < 30 g/L. 7. Hypersensibility to any of to the components of the product. 8. Antecedents or suspicion of malignant diseases by general physical examination, thorax radiography, abdominal and pelvic ultrasound, ginecological examination, rectal tact, PSA. 9. Impossibility to complete with the foresee evaluations and visits. 10. Treatment with any EGF formulation within the 3 previous months. 11. Psychiatric or neurological diseases that impede the patient to give their consent. 12. Alcoholism story in the last two months (consumption not less than 1/4 bottle of rum or 1 bottle of wine or 3 beers, at a frequency not less than 3 times a week) or addiction to drugs in the previous year. 13. Pregnancy or nursing.

研究者

发起方
Center for Genetic Engineering and Biotechnology (CIGB)

相似试验

已完成
1 期
Pharmacokinetics of intralesional EGF in patients with diabetic foot ulcers.Diabetic foot ulcer, Wagner grades 1 or 2Foot UlcerLeg UlcerSkin UlcerDiabetic AngiopathiesVascular DiseasesDiabetes ComplicationsDiabetic NeuropathiesEndocrine System DiseasesCardiovascular DiseasesDiabetic FootDiabetes Mellitus
RPCEC00000047Center for Genetic Engineering and Biotechnology (CIGB), Havana.16
已完成
不适用
Assessing blood levels of ketorolac ( Toradol) injected in around the hip and knee joints in patients undergoing joint replacements
ACTRN12613000923763Dr.Usha Gurunathan18
进行中(未招募)
1 期
Absorption and excretion of melatonin when applied intravenously, rectally, in the bladder, vaginally and dermally in healthy female volunteers
EUCTR2017-000997-13-DKCenter for Perioperative Optimization, Department of Surgery, Herlev Hospital10
进行中(未招募)
1 期
Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitisA total of 8 patients with renal insufficiency and treatment with automated peritoneal dialysis (APD) will be enrolled into this study evaluating the pharmacokinetics of fosfomycin in this special patient group.MedDRA version: 9.1Level: LLTClassification code 10034660Term: Peritoneal dialysis
EUCTR2009-011505-16-ATMedizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin8
已完成
不适用
Pharmacokinetic of methadone in critically ill patientscritically ill patients in ICU.
IRCT2013012610817N3Tehran University of Medical Siences40